News | January 06, 2015

Study That Identifies new Heart Attack Risk Factors to be Published in AACE Journal

Study supports use of new blood test from GD Biosciences that significantly improves identification of at-risk patients

January 6, 2015 — A study that identifies new heart attack risk factors and supports the use of a blood test for detection in patients will be published in the AACE (American Association of Clinical Endocrinologists) Journal.

“There is a great need to correctly identify individuals with active, yet undetected subclinical disease who are at risk of experiencing a coronary event, and for whom early intervention can help,” says Douglas Harrington, M.D., CEO of GD Biosciences and co-author of the study. “Most heart attacks occur at the site of a non-obstructive lesion and many patients do not have symptoms or abnormal lipids.”

GD Biosciences developed the new blood test to help identify patients at risk of suffering a heart attack.

 “Inflammatory Biomarkers & Diabetes as Predictors of CHD in MESA” was also co-authored by Americo Simonini, M.D., attending cardiologist at Cedars Sinai Medical Center, Los Angeles. Simonini says exercise testing or cardiac imaging only diagnose higher-grade coronary stenosis, but fails to identify many at-risk patients who are not showing any symptoms.

The research finds that the use of nine biomarkers and established clinical risk factors (including diabetic status) correlated with the underlying formation of unstable cardiac lesions and significantly improved identification of at-risk patients frequently missed by current methods.

Results demonstrated that the novel protein-biomarker and clinical risk factor algorithm identified patients who went on to experience an acute coronary event. Acute Coronary Syndrome (ACS) is the main cause of coronary artery disease mortality. Insulin resistance and diabetes are significant factors increasing risk of ACS.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init